Psych CASC / OSCE · Consultation-liaison psychiatry
Explaining HD irritability, depression, suicide risk, and tetrabenazine to a spouse — CASC communication station
MRCPsych/FRANZCP-style station: explain HD neuropsychiatry, suicide vigilance, VMAT2–mood link, irritability treatment, and ethics of testing minors.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes after reading time. You are the psychiatry registrar. Neurology remains involved. You meet the spouse alone first.[1]
Candidate instructions. Explain that mood and irritability are common, treatable parts of HD — not simple moral failure. Explain elevated suicide risk and why safety matters. Explain that tetrabenazine can help chorea but may worsen mood, so doses are reviewed jointly. Explain stepped treatment (support, SSRI, cautious antipsychotic if needed) without promising paralysis from 'schizophrenia doses.' Decline secret testing of the asymptomatic child and explain ethics gently. Agree a shared plan that does not stop all neurology medicines abruptly. Avoid inventing legal section numbers.[2][3][4][5]
You have read the opening of this CASC / OSCE. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]van Duijn E, Craufurd D, Hubers AA, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY) J Neurol Neurosurg Psychiatry, 2014.PMID 24828898
- [2]Hubers AA, van Duijn E, Roos RA, et al. Suicidal ideation in a European Huntington's disease population J Affect Disord, 2013.PMID 23876196
- [3]Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology, 2006.PMID 16476934
- [4]Anderson KE, van Duijn E, Craufurd D, et al. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders J Huntingtons Dis, 2018.PMID 30040737
- [5]Walker FO Huntington's disease Lancet, 2007.PMID 17240289